肯尼亚住院儿童出院后5天阿奇霉素疗程对肺炎链球菌携带及耐药的影响
该双盲随机安慰剂对照试验纳入1398名肯尼亚住院儿童,评估出院时5天口服阿奇霉素对肺炎链球菌携带及阿奇霉素耐药比例的影响。结果显示,阿奇霉素组与安慰剂组在出院时、第3个月和第6个月的肺炎链球菌携带率及耐药比例均无显著差异。住院期间高抗生素使用可能削弱了阿奇霉素的额外影响。
要点
- 出院时5天阿奇霉素未改变肺炎链球菌携带率。
- 第3、6个月阿奇霉素耐药比例两组无差异。
- 住院期高抗生素使用可能掩盖阿奇霉素效应。
核心结论
- 阿奇霉素治疗未影响随机化后3或6个月的肺炎链球菌携带或抗菌药物耐药。
研究设计与样本
- 双盲、随机、安慰剂对照试验(NCT02414399),随访1398名肯尼亚住院儿童,按 enroll 县分层1:1随机。
主要发现
- 第3个月携带率65.6% vs 67.0%,PR 0.98(0.90, 1.06);第6个月66.7% vs 66.5%,PR 1.00(0.92, 1.08)。
- 出院时15.7%分离株对阿奇霉素耐药;第3个月耐药比例13.2%(35/266) vs 12.5%(32/256),PR 1.06(0.86, 1.66)。
- 第6个月耐药比例16.7%(41/245) vs 17.6%(43/243),PR 1.01(0.69, 1.49)。
临床怎么用
- 出院时5天阿奇霉素疗程不推荐用于减少肺炎链球菌携带或耐药。
局限性
- 住院期间89.6%(1253/1398)儿童使用抗生素,可能降低阿奇霉素的额外影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Mass azithromycin distribution reduces child mortality in some settings, potentially through reductions in nasopharyngeal carriage of Streptococcus pneumoniae, but has been associated with increased antimicrobial resistance. Individual-level data are lacking on the impact of azithromycin on antimicrobial resistance over time. METHODS: We analyzed data from a double-blind, randomized placebo-controlled trial (ClinicalTrials.gov; NCT02414399) which followed 1398 hospitalized Kenyan children to evaluate the impact of a 5-day course of oral azithromycin at discharge from hospital on pneumococcal carriage and the proportion of isolates (among a random sample) resistant to azithromycin. Randomization to azithromycin or placebo (1:1) was stratified by enrollment county (Kisii or Homa Bay). Using generalized estimating equations, we calculated prevalence ratios (PRs) and 95% CIs for the intervention, adjusting for enrollment site. RESULTS: Overall, 1253/1398 (89.6%) enrolled children received antibiotics during their hospitalization. Pneumococcal carriage at discharge was similar among children randomized to the azithromycin group (158/702 [22.5%]) compared with the placebo group (171/696 [24.6%]; P = .4) and did not differ at month 3 (65.6% versus 67.0%; PR: 0.98 [0.90, 1.06]) or month 6 (66.7% versus 66.5%; PR: 1.00 [0.92, 1.08]). At discharge, 15.7% of isolates were resistant to azithromycin and there was no difference between azithromycin-treated and placebo groups at month 3 (35/266 [13.2%] versus 32/256 [12.5%]; PR: 1.06 [0.86, 1.66]) or month 6 (41/245 [16.7%] versus 43/243 [17.6%]; PR: 1.01 [0.69, 1.49]). CONCLUSIONS: Azithromycin treatment did not effect pneumococcal carriage or antimicrobial resistance 3- or 6-months post-randomization. High inpatient antibiotic use in this recently discharged population may have reduced any further impact of azithromycin.
引用
- Libby TE, Karani A, Tickell KD, et al. The Effect of a 5-Day Course of Azithromycin on Streptococcus Pneumoniae Carriage and Antimicrobial Resistance Among Kenyan Children Discharged From Hospital. J Infect Dis. 2026. PMID: 41542944. doi:10.1093/infdis/jiag028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。